Efficacy of erlotinib on advanced non-small-cell lung cancer
10.3760/cma.j.issn.1006-9801.2011.08.002
- VernacularTitle:厄罗替尼治疗晚期非小细胞肺癌19例临床疗效
- Author:
Mu HU
;
Yi ZHANG
;
Xiuyi ZHI
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Targeted therapy;
Drug therapy
- From:
Cancer Research and Clinic
2011;23(8):509-511
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of erlotinib on advanced NSCLC, and observe its adverse events. Methods An open labeled, expanded access program (EAP) was conducted on 19 pathologically confirmed advanced NSCLC patients who had received at least one regimen chemotherapy.Erlotinib (150 mg) was orally administered daily till disease progression or intolerable adverse events developed.The efficacy was evaluated according to RECIST criteria; the adverse events were evaluated according to NCI criteria.Results In 19 patients, the objective response rate was 21.1% (4/19), and the disease control rate was 84.2 % (16/19); the median progression-free survival time was 7.5 months (3-36 months), and the median survival time was 15.9 months (9-39 months).Adverse events were generally mild (grade Ⅰ or Ⅱ ), including skin rash (84.2 %) and diarrhea (57.9 %). One (5.3 %) patient developed grade Ⅲ elevation of serum glutamate pyruvate transaminase.No grade Ⅳ drug-related adverse event occurred.Conclusion Erlotinib is effective and safe for locally advanced or metastatic NSCLC patients who have failed previous chemotherapy.
